[EN] ARYLPHENYLAMINO-AND ARYLPHENYLETHER-SULFIDE DERIVATIVES, USEFUL FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM [FR] DERIVES D'ARYLPHENYLAMINO- ET D'ARYLPHENYLETHER-SULFIDE
Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing Them
申请人:Guckian Kevin
公开号:US20080234271A1
公开(公告)日:2008-09-25
The present invention relates in part to compounds of formulas (I) and (III): and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a subject.
Arylphenylamino-,Arylphenylamide-, and Arylphenylether-Sulfide Derivatives
申请人:Chin Donovan
公开号:US20070259863A1
公开(公告)日:2007-11-08
The present invention relates in part to compounds of formulas I and III:
and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a subject.
[EN] ARYLPHENYLAMINO-, ARYLPHENYLAMIDE-, AND ARYLPHENYLETHER-SULFIDE DERIVATIVES<br/>[FR] DERIVES DE SULFURE D'ARYLPHENYLAMINE, D'ARYLPHENYLAMIDE, ET D'ARYLPHENYLETHER
申请人:ICOS CORP
公开号:WO2005105770A3
公开(公告)日:2006-03-09
Design and synthesis of a series of meta aniline-based LFA-1 ICAM inhibitors
作者:Kevin M. Guckian、Edward Yin-Shiang Lin、Laura Silvian、Jessica E. Friedman、Donovan Chin、Daniel M. Scott
DOI:10.1016/j.bmcl.2008.08.061
日期:2008.10
A series of meta-substituted anilines were designed and synthesized to inhibit the interaction of LFA-1 with ICAM for the treatment of autoimmune disease. Design of these molecules was performed by utilizing a co-crystal structure for structure-based drug design. The resulting molecules were found to be potent and to possess favorable pharmaceutical properties. (C) 2008 Elsevier Ltd. All rights reserved.
PEVZNER, L. M.;IGNATEV, V. M.;IONIN, B. I., ZH. OBSHCH. XIMII, 1986, 56, N 7, 1470-1472